HK1029916A1 - Use of inosine for the manufacture of a medicamentfor stimulating axonal outgrowth of central nervous system neurons. - Google Patents
Use of inosine for the manufacture of a medicamentfor stimulating axonal outgrowth of central nervous system neurons.Info
- Publication number
- HK1029916A1 HK1029916A1 HK00108201A HK00108201A HK1029916A1 HK 1029916 A1 HK1029916 A1 HK 1029916A1 HK 00108201 A HK00108201 A HK 00108201A HK 00108201 A HK00108201 A HK 00108201A HK 1029916 A1 HK1029916 A1 HK 1029916A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inosine
- nervous system
- central nervous
- medicamentfor
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/921,902 US6440455B1 (en) | 1997-09-02 | 1997-09-02 | Methods for modulating the axonal outgrowth of central nervous system neurons |
PCT/US1998/003001 WO1999011274A1 (en) | 1997-09-02 | 1998-02-20 | Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1029916A1 true HK1029916A1 (en) | 2001-04-20 |
Family
ID=25446158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00108201A HK1029916A1 (en) | 1997-09-02 | 2000-12-19 | Use of inosine for the manufacture of a medicamentfor stimulating axonal outgrowth of central nervous system neurons. |
Country Status (13)
Country | Link |
---|---|
US (8) | US6440455B1 (de) |
EP (2) | EP1466606A3 (de) |
JP (1) | JP4601816B2 (de) |
KR (1) | KR100564789B1 (de) |
CN (1) | CN1286632A (de) |
AT (1) | ATE271874T1 (de) |
AU (1) | AU748961B2 (de) |
CA (1) | CA2302156C (de) |
DE (1) | DE69825292T2 (de) |
HK (1) | HK1029916A1 (de) |
NZ (1) | NZ503073A (de) |
RU (1) | RU2212241C2 (de) |
WO (1) | WO1999011274A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
PT1126826E (pt) * | 1998-11-02 | 2008-11-25 | Elan Pharma Int Ltd | Composição de metilfenidato de libertação modificada multiparticulada |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
US7582680B1 (en) | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
US7172871B1 (en) * | 2000-09-07 | 2007-02-06 | Children's Medical Center Corporation | Methods and compositions for modulating axonal outgrowth of central nervous system neurons |
FR2814077A1 (fr) * | 2000-09-20 | 2002-03-22 | Inst Nat Sante Rech Med | Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs |
US7981420B2 (en) | 2000-12-22 | 2011-07-19 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
EP1389121B1 (de) | 2001-04-24 | 2012-02-22 | Purdue Research Foundation | Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren |
US7147647B2 (en) * | 2002-04-26 | 2006-12-12 | Medtronic, Inc. | Sintered titanium tube for the management of spinal cord injury |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
US7813473B2 (en) * | 2002-07-23 | 2010-10-12 | General Electric Company | Method and apparatus for generating temporally interpolated projections |
US6904118B2 (en) | 2002-07-23 | 2005-06-07 | General Electric Company | Method and apparatus for generating a density map using dual-energy CT |
WO2004022039A2 (en) * | 2002-09-03 | 2004-03-18 | Neurological Technologies Inc. | Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system |
JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル,リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
US7199110B2 (en) * | 2002-12-30 | 2007-04-03 | Purdue Research Foundation | Method of treatment for spinal cord injury |
US7842232B2 (en) * | 2003-05-22 | 2010-11-30 | Elan Pharma International, Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
GB0312844D0 (en) * | 2003-06-04 | 2003-07-09 | Paradigm Therapeutics Ltd | Use of compounds in medicine |
WO2005016359A1 (en) * | 2003-08-19 | 2005-02-24 | Neurological Technologies Inc. | Method of promoting remyelination |
US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
US20080113016A1 (en) * | 2004-07-26 | 2008-05-15 | Gary Steven Firestein | Method for Prevention or Treatment of Inflammatory Disease |
WO2006023530A2 (en) * | 2004-08-16 | 2006-03-02 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
WO2006111348A1 (de) * | 2005-04-18 | 2006-10-26 | Abbott Gmbh & Co. Kg | Verwendung von heparin und heparinderivaten zur modulation des neuritenwachstum-kontrollierenden nogo-rezeptors |
WO2007039256A2 (de) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
EP2004139A1 (de) * | 2006-03-31 | 2008-12-24 | Adenobio N.V. | Zusammensetzungen, verfahren und kits mit adenosin und inosin in kombination zur diagnose und behandlung |
BRPI0714173A2 (pt) * | 2006-07-12 | 2012-12-25 | Elan Pharma Int Ltd | composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem |
US20080140008A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
US20080270686A1 (en) * | 2007-04-26 | 2008-10-30 | Grannan Michael F | Methods and system to cache content on a vehicle |
US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2259677A4 (de) * | 2008-02-29 | 2011-11-02 | Alseres Pharmaceuticals Inc | Systemische purinverabreichung zur modulation des axonalen wachstums des zentralnervensystems |
CA2724199C (en) | 2008-06-06 | 2016-07-26 | Children's Medical Center Corporation | Promoting axon regeneration in the adult cns through control of protein translation |
EP2510001B1 (de) | 2009-12-08 | 2015-12-02 | AbbVie Deutschland GmbH & Co KG | Monoklonale antikörper gegen das rgm-a-protein zur behandlung von degenerationen der retinalen nervenfaserschicht |
LT2807192T (lt) | 2012-01-27 | 2018-07-25 | AbbVie Deutschland GmbH & Co. KG | Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui |
US20140179741A1 (en) * | 2012-10-10 | 2014-06-26 | Massachusetts Institute Of Technology | Use of chelators of divalent cations to promote nerve regeneration |
WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
RU2517117C2 (ru) * | 2012-11-26 | 2014-05-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) | Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций |
US10682372B2 (en) | 2015-08-26 | 2020-06-16 | Stagen Co., Ltd. | Intracellular ATP enhancer |
WO2020140730A1 (zh) * | 2018-12-30 | 2020-07-09 | 广州君赫生物科技有限公司 | 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用 |
EP3797764A1 (de) | 2019-09-27 | 2021-03-31 | Janusz Chupty Contissi | Pharmakologische zusammensetzung zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz, und die verwendung von substanzen der gruppe j05 atc zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz |
US11311565B2 (en) | 2020-06-25 | 2022-04-26 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for promoting axonal regeneration |
EP4408531A1 (de) * | 2021-09-28 | 2024-08-07 | University of Pittsburgh - of the Commonwealth System of Higher Education | Verfahren zur behandlung von peripherer neuropathie |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3808027A (en) | 1972-03-29 | 1974-04-30 | Du Pont | Silica surfaced films |
US4341868A (en) * | 1978-08-18 | 1982-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Method and test composition for the determination of the substrate for xanthine oxidase |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
AU1727188A (en) | 1987-05-26 | 1988-12-21 | Paul Gordon | Polymorphs of inosine and methods of making and using them |
US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
JPH05506842A (ja) * | 1989-09-15 | 1993-10-07 | ジェンシア・ファーマシュウティカルズ・インコーポレイテッド | 神経変性状態の処置方法 |
US5187162A (en) | 1989-09-15 | 1993-02-16 | Gensia Pharmaceuticals | Methods of treating neurodegenerative conditions |
FR2692784B1 (fr) * | 1992-06-24 | 1995-06-30 | Pf Medicament | Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux. |
US5483130A (en) * | 1992-09-09 | 1996-01-09 | Axelerator, Inc. | Structure for accelerating heavy ions with uniformly spaced quadrupole focusing (USQF) |
US5422343A (en) * | 1992-12-21 | 1995-06-06 | Otsuka Pharmaceutical Factory, Inc. | Prophylactic and therapeutic composition for MRSA infection |
US5438130A (en) * | 1993-01-15 | 1995-08-01 | Cambridge Neuroscience, Inc. | Fucosylated guanosine disulfates as excitatory amino acid antagonists |
RU2063753C1 (ru) | 1993-04-22 | 1996-07-20 | Василий Владимирович Афанасьев | Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом |
WO1995005177A1 (fr) * | 1993-08-13 | 1995-02-23 | Seikagaku Corporation | Remede contre les maladies nerveuses |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5447939A (en) * | 1994-07-25 | 1995-09-05 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
AU4808997A (en) * | 1996-09-30 | 1998-04-24 | Brigham And Women's Hospital | Methods and compounds for treatment of abnormal uterine bleeding |
US6440455B1 (en) * | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
US6855690B2 (en) * | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
GB2379797A (en) * | 2001-09-15 | 2003-03-19 | Zarlink Semiconductor Ab | Surface Emitting Laser |
-
1997
- 1997-09-02 US US08/921,902 patent/US6440455B1/en not_active Expired - Fee Related
-
1998
- 1998-02-20 AT AT98908565T patent/ATE271874T1/de not_active IP Right Cessation
- 1998-02-20 CA CA002302156A patent/CA2302156C/en not_active Expired - Fee Related
- 1998-02-20 WO PCT/US1998/003001 patent/WO1999011274A1/en not_active Application Discontinuation
- 1998-02-20 NZ NZ503073A patent/NZ503073A/xx unknown
- 1998-02-20 KR KR1020007002226A patent/KR100564789B1/ko not_active IP Right Cessation
- 1998-02-20 RU RU2000108443/14A patent/RU2212241C2/ru not_active IP Right Cessation
- 1998-02-20 DE DE69825292T patent/DE69825292T2/de not_active Expired - Lifetime
- 1998-02-20 JP JP2000508376A patent/JP4601816B2/ja not_active Expired - Fee Related
- 1998-02-20 AU AU66568/98A patent/AU748961B2/en not_active Ceased
- 1998-02-20 EP EP04009962A patent/EP1466606A3/de not_active Withdrawn
- 1998-02-20 CN CN98810807A patent/CN1286632A/zh active Pending
- 1998-02-20 EP EP98908565A patent/EP1009412B1/de not_active Expired - Lifetime
-
2000
- 2000-12-19 HK HK00108201A patent/HK1029916A1/xx not_active IP Right Cessation
-
2001
- 2001-11-29 US US09/997,687 patent/US20020055484A1/en not_active Abandoned
- 2001-11-29 US US09/997,688 patent/US6551612B2/en not_active Expired - Lifetime
-
2002
- 2002-05-14 US US10/144,952 patent/US20020137721A1/en not_active Abandoned
- 2002-05-14 US US10/145,224 patent/US20020128223A1/en not_active Abandoned
-
2003
- 2003-03-10 US US10/385,031 patent/US20040014710A1/en not_active Abandoned
-
2005
- 2005-05-19 US US11/132,701 patent/US7338666B2/en not_active Expired - Fee Related
-
2007
- 2007-02-16 US US11/708,098 patent/US7935680B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050277614A1 (en) | 2005-12-15 |
AU6656898A (en) | 1999-03-22 |
JP4601816B2 (ja) | 2010-12-22 |
US20020042390A1 (en) | 2002-04-11 |
EP1466606A2 (de) | 2004-10-13 |
US20020137721A1 (en) | 2002-09-26 |
ATE271874T1 (de) | 2004-08-15 |
RU2000108443A (ru) | 2002-02-10 |
US20020055484A1 (en) | 2002-05-09 |
US20020128223A1 (en) | 2002-09-12 |
US20040014710A1 (en) | 2004-01-22 |
EP1009412A1 (de) | 2000-06-21 |
NZ503073A (en) | 2002-11-26 |
JP2001516695A (ja) | 2001-10-02 |
CA2302156C (en) | 2006-11-21 |
KR100564789B1 (ko) | 2006-03-28 |
RU2212241C2 (ru) | 2003-09-20 |
DE69825292T2 (de) | 2005-05-25 |
US7935680B2 (en) | 2011-05-03 |
US6551612B2 (en) | 2003-04-22 |
CN1286632A (zh) | 2001-03-07 |
KR20010023578A (ko) | 2001-03-26 |
WO1999011274A1 (en) | 1999-03-11 |
US7338666B2 (en) | 2008-03-04 |
DE69825292D1 (de) | 2004-09-02 |
EP1009412B1 (de) | 2004-07-28 |
CA2302156A1 (en) | 1999-03-11 |
AU748961B2 (en) | 2002-06-13 |
US6440455B1 (en) | 2002-08-27 |
US20070213294A1 (en) | 2007-09-13 |
EP1466606A3 (de) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1029916A1 (en) | Use of inosine for the manufacture of a medicamentfor stimulating axonal outgrowth of central nervous system neurons. | |
PL320822A1 (en) | Sulphonamidic compounds as therapeutic agents for treatment of central nervous system, method of obtaining novel sulphonamidic compounds and drugs containing such compounds | |
IL105586A0 (en) | Lactone derivatives,processes for their preparation and their use as medicaments | |
HK1046274A1 (en) | Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders. | |
IL104006A0 (en) | Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them | |
ZA937951B (en) | Prodrugs,their preparation and use as pharmaceuticals | |
HUP9601566A2 (en) | Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component | |
HK1020956A1 (en) | Oxadiazoles, processes for their preparation and their use as medicaments | |
SI0751129T1 (en) | Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | |
IL112664A0 (en) | 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
ITRM920412A0 (it) | Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico. | |
CA2135709A1 (en) | Melatonin derivatives for use in treating sleep disorders | |
HK1014938A1 (en) | Oxazolidinone derivatives, their preparation and therapeutical use | |
HUP9600665A3 (en) | Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation | |
ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
PT935598E (pt) | Derivados de 3-oxo-pirido (1,2-a)benzimidazole-4-carboxamida alquilo substituidos contendo 5 heteroatomos uteis no tratamento de disturbios do sistema nervoso central | |
NZ320323A (en) | Amine derivatives of epipodophyllotoxin 2", 3"- dideoxyglycosides, preparation and use thereof as a drug and for treating cancer | |
GR3035710T3 (en) | Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds as well as medicaments containing them | |
SG46249A1 (en) | Novel phospholipid derivatives | |
AU4845196A (en) | 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient | |
FR2699920B1 (fr) | Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique. | |
FR2700546B1 (fr) | Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique. | |
ZA928127B (en) | Use of substituted pyrrolidines, some of which are known, as medicaments, new active substances and processes for their preparation. | |
ZA928126B (en) | Use of substituted tetrahydrothiophenes, some of wich are known as medicaments, new active substances and processes for their preparation. | |
EP0897988A4 (de) | Physiologisch aktive tkr1785's substanzen, verfahren zu ihrer herstellung und mikrobe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130220 |